Measured in a cell proliferation assay using HUVEC cells,the EC50 for this effect is less than
2ng/ml.
Immobilized VEGF-121, Human (Cat. No. UA040082) at 0.5μg/mL (100μL/well) can bind Bevacizumab (starter-bio, Cat. No. S0B0437) with EC50 of 1.20-1.54 ng/mL.
Immobilized VEGF-121, Human (Cat. No. UA040082) at 2.0μg/mL (100μL/well) can bind VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144) with EC50 of 8.25-11.55 ng/mL.
评论(0)